Journal of Allergy and Clinical Immunology: Global (Nov 2024)

Daratumumab-based treatment of monoclonal gammopathy–associated angioedema due to acquired C1-inhibitor deficiency

  • Remy S. Petersen, MD,
  • Lauré M. Fijen, MD, PhD,
  • Laurens E. Franssen, MD, PhD,
  • Josephine M.I. Vos, MD, PhD,
  • Danny M. Cohn, MD, PhD

Journal volume & issue
Vol. 3, no. 4
p. 100322

Abstract

Read online

Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

Keywords